BioPharmSignal logoBioPharmSignal

Biotech News

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

NewAmsterdam Pharma (NAMS)NewAmsterdam PharmaCompany update

NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”)

Related news

NAMSNewAmsterdam Pharma2026-07-01 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

NAMSNewAmsterdam Pharma2026-08-26 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

LXRXLexicon Pharmaceuticals2026-06-03 12:00 EST

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

BLTEBelite Bio2026-08-21 12:00 EST

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

RYTMRhythm Pharmaceuticals2026-09-10 12:00 EST

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

VANIVivani Medical2026-09-03 20:08 EST

Vivani Medical Announces Participation in Upcoming Investor Conferences

VKTXViking Therapeutics2026-09-02 20:05 EST

Viking Therapeutics to Participate at Upcoming Investor Conferences

MNKDMannKind2026-09-02 12:30 EST

MannKind to Present at Upcoming Investor Conferences

MISTMilestone Pharmaceuticals Inc.2026-09-02 12:00 EST

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

SGMTSagimet Biosciences2026-09-02 11:00 EST

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

View all latest news

NewAmsterdam Pharma

Oral Lipid-Lowering Therapies NewAmsterdam Pharma develops oral therapies for cardiovascular disease. Its lead program targets CETP to produce substantial reductions in LDL cholesterol. Obicetrapib Obicetrapib is an oral CETP inhibitor being developed for patients who need additional LDL reduction despite existing lipid-lowering...

Recent company news

NAMSNewAmsterdam Pharma2026-09-03 20:01 EST

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAMSNewAmsterdam Pharma2026-09-02 12:00 EST

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September

NAMSNewAmsterdam Pharma2026-08-26 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

NAMSNewAmsterdam Pharma2026-08-06 20:01 EST

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAMSNewAmsterdam Pharma2026-08-05 11:00 EST

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Stock data

Close
21.93 USD
Market cap
3.71B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States